Kyverna Therapeutics, Inc.
KYTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $7 | $6 |
| % Growth | – | -100% | 24.2% | – |
| Cost of Goods Sold | $2 | $2 | $0 | $0 |
| Gross Profit | -$2 | -$2 | $7 | $6 |
| % Margin | – | – | 100% | 100% |
| R&D Expenses | $112 | $48 | $28 | $26 |
| G&A Expenses | $30 | $0 | $8 | $6 |
| SG&A Expenses | $30 | $12 | $8 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$2 | $0 | $0 | $0 |
| Operating Expenses | $140 | $61 | $36 | $32 |
| Operating Income | -$143 | -$62 | -$29 | -$26 |
| % Margin | – | – | -418.3% | -465.8% |
| Other Income/Exp. Net | $15 | $2 | $0 | -$0 |
| Pre-Tax Income | -$127 | -$60 | -$29 | -$26 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$127 | -$60 | -$29 | -$26 |
| % Margin | – | – | -411.3% | -465.9% |
| EPS | -3.33 | -0 | -1.12 | -1.02 |
| % Growth | -3,329,900% | 100% | -9.8% | – |
| EPS Diluted | -3.33 | -0 | -1.12 | -1.02 |
| Weighted Avg Shares Out | 38 | 674 | 26 | 26 |
| Weighted Avg Shares Out Dil | 38 | 674 | 26 | 26 |
| Supplemental Information | – | – | – | – |
| Interest Income | $15 | $2 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $2 | $1 | $1 |
| EBITDA | -$125 | -$58 | -$28 | -$26 |
| % Margin | – | – | -395.4% | -455.5% |